Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- asciminib
- elderberry
Interactions between your drugs
elderberry asciminib
Applies to: elderberry, asciminib
Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants. However, clinical cases of drug interactions have not been reported.
References (8)
- Miller LG (1998) "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med, 158, p. 2200-11
- Pepping J (1999) "Echinacea." Am J Health Syst Pharm, 56, p. 121-2
- Izzo AA, Ernst E (2001) "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs, 61, p. 2163-75
- Therapeutic Research Faculty (2008) Natural Medicines Comprehensive Database. http://www.naturaldatabase.com
- (2024) "Product Information. Ashwagandha (ashwagandha)." Now Foods, 1
- (2024) "Product Information. Vyvgart (efgartigimod alfa)." Argenx UK Ltd
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Office of Dietary Supplements Ashwagandha https://www.nccih.nih.gov/health/ashwagandha
- Barak V, Halperin T, Kalickman I (2001) "The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines" Eur Cytokine Netw, 12, p. 290-6
Drug and food interactions
asciminib food
Applies to: asciminib
ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of asciminib. When a single 40 mg dose of asciminib was administered with a low-fat meal (400 calories; 25% fat) in healthy volunteers, asciminib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 35% and 30%, respectively, compared to asciminib administered in the fasted state. Administration with a high-fat meal (1000 calories; 50% fat) decreased the Cmax and AUC of asciminib by 68% and 62%, respectively.
MANAGEMENT: To ensure adequate asciminib exposures, food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib.
References (2)
- (2021) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals
- (2022) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals UK Ltd, Scemblix 20 mg film-
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Scemblix
Scemblix (asciminib) is an oral kinase inhibitor that may be used to treat adults with a type of ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Iclusig
Iclusig (ponatinib) used to treat a type of blood cancer called chronic myeloid leukemia (CML), or ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.